169 related articles for article (PubMed ID: 25270431)
1. Targeting DNA vaccines to myeloid cells using a small peptide.
Ye C; Choi JG; Abraham S; Shankar P; Manjunath N
Eur J Immunol; 2015 Jan; 45(1):82-8. PubMed ID: 25270431
[TBL] [Abstract][Full Text] [Related]
2. The relative contribution of antibody and CD8+ T cells to vaccine immunity against West Nile encephalitis virus.
Shrestha B; Ng T; Chu HJ; Noll M; Diamond MS
Vaccine; 2008 Apr; 26(16):2020-33. PubMed ID: 18339459
[TBL] [Abstract][Full Text] [Related]
3. Antigen-specific cytotoxic T lymphocytes protect against lethal West Nile virus encephalitis.
Purtha WE; Myers N; Mitaksov V; Sitati E; Connolly J; Fremont DH; Hansen TH; Diamond MS
Eur J Immunol; 2007 Jul; 37(7):1845-54. PubMed ID: 17559174
[TBL] [Abstract][Full Text] [Related]
4. Single-chain HLA-A2 MHC trimers that incorporate an immundominant peptide elicit protective T cell immunity against lethal West Nile virus infection.
Kim S; Li L; McMurtrey CP; Hildebrand WH; Weidanz JA; Gillanders WE; Diamond MS; Hansen TH
J Immunol; 2010 Apr; 184(8):4423-30. PubMed ID: 20212098
[TBL] [Abstract][Full Text] [Related]
5. Induction of potent Th1-type immune responses from a novel DNA vaccine for West Nile virus New York isolate (WNV-NY1999).
Yang JS; Kim JJ; Hwang D; Choo AY; Dang K; Maguire H; Kudchodkar S; Ramanathan MP; Weiner DB
J Infect Dis; 2001 Oct; 184(7):809-16. PubMed ID: 11550123
[TBL] [Abstract][Full Text] [Related]
6. Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge.
De Filette M; Soehle S; Ulbert S; Richner J; Diamond MS; Sinigaglia A; Barzon L; Roels S; Lisziewicz J; Lorincz O; Sanders NN
PLoS One; 2014; 9(2):e87837. PubMed ID: 24503579
[TBL] [Abstract][Full Text] [Related]
7. A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII.
Schneeweiss A; Chabierski S; Salomo M; Delaroque N; Al-Robaiy S; Grunwald T; Bürki K; Liebert UG; Ulbert S
Vaccine; 2011 Aug; 29(37):6352-7. PubMed ID: 21596075
[TBL] [Abstract][Full Text] [Related]
8. Induction of Epstein-Barr virus-specific cytotoxic T-lymphocyte responses using dendritic cells pulsed with EBNA-3A peptides or UV-inactivated, recombinant EBNA-3A vaccinia virus.
Subklewe M; Chahroudi A; Schmaljohn A; Kurilla MG; Bhardwaj N; Steinman RM
Blood; 1999 Aug; 94(4):1372-81. PubMed ID: 10438725
[TBL] [Abstract][Full Text] [Related]
9. Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene.
Wiktor TJ; Macfarlan RI; Reagan KJ; Dietzschold B; Curtis PJ; Wunner WH; Kieny MP; Lathe R; Lecocq JP; Mackett M
Proc Natl Acad Sci U S A; 1984 Nov; 81(22):7194-8. PubMed ID: 6095272
[TBL] [Abstract][Full Text] [Related]
10. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects.
Storni T; Ruedl C; Schwarz K; Schwendener RA; Renner WA; Bachmann MF
J Immunol; 2004 Feb; 172(3):1777-85. PubMed ID: 14734761
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and protective efficacy of recombinant Modified Vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens.
Volz A; Lim S; Kaserer M; Lülf A; Marr L; Jany S; Deeg CA; Pijlman GP; Koraka P; Osterhaus AD; Martina BE; Sutter G
Vaccine; 2016 Apr; 34(16):1915-26. PubMed ID: 26939903
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the immune response elicited by the vaccinia virus L3 protein delivered as naked DNA.
Ramírez M; Santos S; Martínez O; Rodríguez R; Miranda E; Ramos-Perez WD; Otero M
Vaccine; 2018 Apr; 36(15):2049-2055. PubMed ID: 29525282
[TBL] [Abstract][Full Text] [Related]
13. Virological and preclinical characterization of a dendritic cell targeting, integration-deficient lentiviral vector for cancer immunotherapy.
Odegard JM; Kelley-Clarke B; Tareen SU; Campbell DJ; Flynn PA; Nicolai CJ; Slough MM; Vin CD; McGowan PJ; Nelson LT; Ter Meulen J; Dubensky TW; Robbins SH
J Immunother; 2015; 38(2):41-53. PubMed ID: 25658613
[TBL] [Abstract][Full Text] [Related]
14. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
[TBL] [Abstract][Full Text] [Related]
15. A West Nile virus NS4B-P38G mutant strain induces adaptive immunity via TLR7-MyD88-dependent and independent signaling pathways.
Xie G; Welte T; Wang J; Whiteman MC; Wicker JA; Saxena V; Cong Y; Barrett AD; Wang T
Vaccine; 2013 Aug; 31(38):4143-51. PubMed ID: 23845800
[TBL] [Abstract][Full Text] [Related]
16. A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice.
Spohn G; Jennings GT; Martina BE; Keller I; Beck M; Pumpens P; Osterhaus AD; Bachmann MF
Virol J; 2010 Jul; 7():146. PubMed ID: 20604940
[TBL] [Abstract][Full Text] [Related]
17. Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles.
Storni T; Lechner F; Erdmann I; Bächi T; Jegerlehner A; Dumrese T; Kündig TM; Ruedl C; Bachmann MF
J Immunol; 2002 Mar; 168(6):2880-6. PubMed ID: 11884458
[TBL] [Abstract][Full Text] [Related]
18. A single immunization with a minute dose of a lentiviral vector-based vaccine is highly effective at eliciting protective humoral immunity against West Nile virus.
Iglesias MC; Frenkiel MP; Mollier K; Souque P; Despres P; Charneau P
J Gene Med; 2006 Mar; 8(3):265-74. PubMed ID: 16308885
[TBL] [Abstract][Full Text] [Related]
19. Targeting viral antigens to CD11c on dendritic cells induces retrovirus-specific T cell responses.
Ejaz A; Ammann CG; Werner R; Huber G; Oberhauser V; Hörl S; Schimmer S; Dittmer U; von Laer D; Stoiber H; Bánki Z
PLoS One; 2012; 7(9):e45102. PubMed ID: 23028784
[TBL] [Abstract][Full Text] [Related]
20. A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse.
El Garch H; Minke JM; Rehder J; Richard S; Edlund Toulemonde C; Dinic S; Andreoni C; Audonnet JC; Nordgren R; Juillard V
Vet Immunol Immunopathol; 2008 Jun; 123(3-4):230-9. PubMed ID: 18372050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
